EC Number   |
Expression |
Reference |
|---|
   1.4.3.13 | down |
ability of torasemide to correct both lysyl oxidase overexpression and enhanced collagen cross-linking |
698212 |
| 1.4.3.13 | down |
in MIA Paca-2 cells, silencing of apecific protein 1 (SP1) induces a reduction of LOXL2 expression |
765826 |
| 1.4.3.13 | down |
lineage-specific mutation of the type II TGFbeta receptor gene, Tgfbetar2, in both neural crest- and mesoderm-derived vascular smooth muscle precursors leads to absence of TGFbeta receptor function and reduced lysyl oxidase expression. The result is a poorly organized vascular elastic matrix in late-stage embryos, which is prone to dilation and aneurysm, due to a failure to initiate formation of the elastic matrix, rather than a failure to maintain a preexisting matrix, phenotype of Wnt1Cre/Tgfbr2 mutant embryos, overview |
698112 |
| 1.4.3.13 | down |
tumor suppressor Pdcd4 inhibits LOX expression, loss of Pdcd4 in human nonmetastatic breast cancer cells increases the expression of LOX mRNA |
713156 |
| 1.4.3.13 | more |
the enzyme expression is not influenced by diurnal variations, but significantly by the gender, female mice show lower enzyme mRNA expression than male ones |
696829 |
| 1.4.3.13 | up |
enzyme expression is induced by TGFbeta treatment in smooth muscle cells |
698112 |
| 1.4.3.13 | up |
LOX and LOXL2 are induced 13 and 7.5fold, respectively, by hypoxia-inducible transcription factor-1alpha and hypoxia-inducible transcription factor-2beta |
725411 |
| 1.4.3.13 | up |
LOX is induced by hypoxia, loss of Pdcd4 in human nonmetastatic breast cancer cells increases the expression of LOX mRNA, and loss of Pdcd4 also augments hypoxia induction of LOX |
713156 |
| 1.4.3.13 | up |
on day 5, the signals for Lox mRNA and protein are detected in the subluminal stroma surrounding the implanting blastocyst at implantation sites while no signal is observed at interimplantation sites. From days 6 to 8 of pregnancy, the signals for Lox mRNA and protein are strongly detected in the decidual cells. The expression of Lox is under the control of estrogen via the GSK-3beta/beta-catenin/c-myc pathway |
-, 764665 |
| 1.4.3.13 | up |
the enzyme is highly up-regulated in metastatic breast cancer cells and tissues |
725545 |
